Liquidia Announces FDA Acceptance of New Drug Application for LIQ861 (treprostinil) Inhalation Powder for the Treatment of Pulmonary Arterial HypertensionGlobeNewsWire • 04/08/20
Liquidia Technologies, Inc. (LQDA) CEO Neal Fowler on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 03/11/20
Liquidia Technologies, Inc. (LQDA) Reports Q4 Loss, Misses Revenue EstimatesZacks Investment Research • 03/11/20
Will Liquidia Technologies, Inc. (LQDA) Report Negative Earnings Next Week?Zacks Investment Research • 03/04/20
Liquidia Technologies stock soars after Wedbush says private placement gives company runway through Q4 2020Market Watch • 12/26/19
Liquidia Technologies Inc. (LQDA) CEO Neal Fowler on Q3 2019 Results - Earnings Call TranscriptSeeking Alpha • 11/13/19
Liquidia Technologies Appoints Industry Veteran Katie Rielly-Gauvin to Board of DirectorsGlobeNewsWire • 11/01/19
Liquidia Technologies, Inc. (LQDA) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseZacks Investment Research • 10/23/19
Liquidia Technologies Appoints Industry Veteran Dr. Joanna Horobin to Board of DirectorsGlobeNewsWire • 09/12/19
Liquidia Technologies Inc. (LQDA) CEO Neal Fowler on Q2 2019 Results - Earnings Call TranscriptSeeking Alpha • 08/08/19
Liquidia Technologies: Targeting Pulmonary Arterial Hypertension Using Proprietary Drug Particle Generating PlatformSeeking Alpha • 06/10/19
Liquidia Technologies Inc. (LQDA) CEO Neal Fowler on Q1 2019 Results - Earnings Call TranscriptSeeking Alpha • 05/06/19